Gadeta's Acquisition

Gadeta was acquired by Gilead Sciences on July 19, 2018.

Gadeta has developed a technology platform based on combinatorial T Cell receptor exchange (CTE) to create optimized gamma delta (γδ) T-cell receptors (TCRs) with an enhanced anti-cancer reactivity.…

Articles about Gadeta's Acquisition: